Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP March 31, 2026 11:00 AM EDT
Company Participants
Helen Sabzevari – President, CEO & Director
Phil Tennant – Chief Commercial Officer
Conference Call Participants
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division
Presentation
Swayampakula Ramakanth
H.C. Wainwright & Co, LLC, Research Division
Good morning. I’m RK, a senior sell-side biotech analyst at H.C. Wainwright. So — and we are thrilled to be hosting Precigen for this fireside chat this morning. So 2025 has been a transformational year for Precigen, marked by the landmark FDA approval of PAPZIMEOS, the first immunotherapy for adult RRP. So as we sit here in late March of 2026, the company has officially transitioned into a commercial stage entity reporting its first quarter of launch very recently.
So joining us today are Dr. Helen Sabzevari, President and CEO; and Phil Tennant, Chief Commercial Officer. Good morning, folks, and thank you very much for joining us this morning.
Question-and-Answer Session
Swayampakula Ramakanth
H.C. Wainwright & Co, LLC, Research Division
Helen, as we get started, especially with your experience of developing various therapies. And now with this particular one, PAPZIMEOS. So how do you see this new excursion with this drug. And also, if you can, please describe the molecule itself and what it does for this particular set of patients?
Helen Sabzevari
President, CEO & Director
Well, first of all, I would like to take the opportunity to thank you, RK, for having us and also to say good morning to the audience here. Clearly, the PAPZIMEOS molecule at the center of all of this for the recurrent respiratory Papillomatosis is a very innovative molecule and the premise of this molecule is built on AdenoVerse platform that we have at Precigen, which, by the way, we fully have the ownership of